RECRUITING

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

Official Title

Care cOordination Using Mobile Technology to Enhance Patient Empowerment in Acute Comorbidities to aSSess Improvement in Outcomes in Hospital readmissioNs

Quick Facts

Study Start:2021-02-18
Study Completion:2026-12-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04905160

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2
  2. 2. All subjects 18 years or above will be a criteria for inclusion for Phase 1
  3. 3. For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;
  4. 4. For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status
  5. 5. Patients considered unreliable by the investigator concerning the requirements for follow-up visits

Contacts and Locations

Study Contact

Navin Govind
CONTACT
2317942328
vitalbeat@aventyn.com
Sharolynn Mclurg
CONTACT

Principal Investigator

Kris Vijay, MD
STUDY_CHAIR
Abrazo Arizona Heart
Raj Bhat, MD
STUDY_DIRECTOR
Pioneer Hospitalists
Zaki Lababidi, MD
PRINCIPAL_INVESTIGATOR
Gilbert Cardiology
Ashok Solsi, MD
PRINCIPAL_INVESTIGATOR
Premier Cardiovascular Center

Study Locations (Sites)

Multiple Locations
Phoenix, Arizona, 85016
United States

Collaborators and Investigators

Sponsor: Aventyn, Inc.

  • Kris Vijay, MD, STUDY_CHAIR, Abrazo Arizona Heart
  • Raj Bhat, MD, STUDY_DIRECTOR, Pioneer Hospitalists
  • Zaki Lababidi, MD, PRINCIPAL_INVESTIGATOR, Gilbert Cardiology
  • Ashok Solsi, MD, PRINCIPAL_INVESTIGATOR, Premier Cardiovascular Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-02-18
Study Completion Date2026-12-22

Study Record Updates

Study Start Date2021-02-18
Study Completion Date2026-12-22

Terms related to this study

Additional Relevant MeSH Terms

  • Heart Failure
  • ADHF
  • Acute MI